Verana Health, a San Francisco, CA-based digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, raised $150m in Series E funding.
The round was led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings with participation from existing investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers, as well as new investors including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. Jeffrey Low, MD, Principal at Novo Growth, and a representative from JJDC have joined Verana Health’s Board of Directors.
The company intends to use the funds to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships.
Led by Sujay Jadhav, CEO, Verana Health is a digital health company committed to delivering quality drug lifecycle and medical practice insights from an exclusive real-world data network. Verana Health is entrusted by key specialty medical societies to manage data from more than 20,000 healthcare providers and 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a population health data engine that securely powers a data integrity feedback loop of nearly a half-billion, point-of-care health encounters. By applying advanced analytics to fit-for-purpose, quality data sets, Qdata™, the company helps life sciences collaborators generate real-world evidence, advance business insights, and accelerate medical innovations that promote quality of care and quality of life.
Verana Health is the exclusive data partner of the American Academy of Ophthalmology, American Urological Association, and American Academy of Neurology and collaborates with multinational pharmaceutical companies as well as emerging biotechnology and biopharmaceutical companies.
FinSMEs
25/01/2022